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Aims Adherence to evidence-based treatments and its consequences after acute myocardial infarction (MI) are poorly
defined. We examined the extent to which clopidogrel treatment initiated in hospital is continued in primary
care; the factors predictive of clopidogrel discontinuation and the hazard of death or recurrent MI.
Methods and
results
We linked the Myocardial Ischaemia National Audit Project registry and the General Practice Research Database to
examine adherence to clopidogrel in primary care among patients discharged from hospital after MI (2003–2009). Hos-
pital Episode Statistics and national mortality data were linked, documenting all-cause mortality and non-fatal MI. Of the
7543 linked patients, 4650 were prescribed clopidogrel in primary care within 3 months of discharge. The adjusted odds
of still being prescribed clopidogrel at 12 months were similar following non-ST-elevation myocardial infarction
(NSTEMI) 53% (95% CI, 51–55) and ST-elevation myocardial infarction (STEMI) 54% (95% CI, 52–56), but contrast
with statins: NSTEMI 84% (95% CI, 82–85) and STEMI 89% (95% CI, 87–90). Discontinuation within 12 months
was more frequent in older patients [.80 vs. 40–49 years, adjusted hazard ratio (HR) 1.50 (95% CI, 1.15–1.94)]
and with bleeding events [HR 1.34 (95% CI, 1.03–1.73)]. 18.15 patients per 100 person-years (95% CI, 16.83–
19.58) died or experienced non-fatal MI in the first year following discharge. In patients who discontinued clopidogrel
within 12 months, the adjusted HR for death or non-fatal MI was 1.45 (95% CI, 1.22–1.73) compared with untreated
patients, and 2.62 (95% CI, 2.17–3.17) compared with patients persisting with clopidogrel treatment.
Conclusion This is the first study to use linked registries to determine persistence of clopidogrel treatment after MI in primary
care. It demonstrates that discontinuation is common and associated with adverse outcomes.
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Introduction
Dual anti-platelet therapy with aspirin and clopidogrel reduces the
risk of thrombotic events and is recommended in the management
of acute coronary syndromes.1 –4 National Institute for Health and
Clinical Excellence (NICE) guideline recommendations are for
treatment with clopidogrel to continue for 12 months after
non-ST-elevation myocardial infarction (NSTEMI),1 but for only
30 days or 3 months after ST-elevation MI (STEMI), increasing to
12 months if a drug-eluting stent has been deployed.1,2 However,
the optimal duration of clopidogrel treatment after coronary stent-
ing is still in doubt5 and late stent thrombosis may occur even with
discontinuation beyond 12 months.6 Of greater concern is the
hazard of premature discontinuation of clopidogrel and recent
data have shown that in patients who do not fill their prescriptions
early after hospital discharge the risk of MI or death is significantly
increased.7 This takes no account of the potential risk associated
with discontinuation of treatment later after discharge, although
there is little information available about patient adherence to clo-
pidogrel therapy after MI. Data for statin therapy, however, suggest
that discontinuation of evidence-based therapy is not uncommon
during the first 12 months and may have important clinical
consequences.8
The Myocardial Ischaemia National Audit Project (MINAP) reg-
istry in the UK records data, including discharge medications, for
patients with MI in all 230 acute hospital trusts in England and
Wales.9 Information on continuing treatment in primary care is
available from prescription records within the General Practice
Research Database (GPRD) that contains the complete anon-
ymized primary care medical records for general practices that
are registered with a panel of general practices and use Vision soft-
ware (8% of the UK population).10 In order to document relations
between clopidogrel discontinuation and coronary events in the 12
months after NSTEMI and STEMI, we have linked the MINAP and
GPRD registries, and documented outcomes through further
linkage with the Hospital Episodes Statistics register and the
Office of National Statistics Mortality Data. Our specific objectives
were (i) to define the extent to which clopidogrel treatment
(initiated in hospital) is continued in primary care, (ii) to identify
factors predictive of clopidogrel discontinuation, and (iii) to
analyse the hazard of death or recurrent MI associated with
clopidogrel discontinuation.
Methods
This is a retrospective observational cohort study using linked data
from the MINAP, GPRD, Hospital Episode Statistics (HES), and
death certificates.9,10 The protocol was reviewed by independent
scientific committees with experience in GPRD and MINAP.
Linkage
In England, for each hospitalized patient, HES records dates of admis-
sion and discharge and main diagnoses. For the linkage, a Trusted Third
Party used patient identifiers, including the patient’s NHS number, date
of birth, and postcode to link GPRD to MINAP, HES, and death certi-
ficates. After this linkage, all the patient identifiers were removed and
researchers had access only to anonymized information. The data were
linked for 224 of 592 (38%) GPRD practices, as the linkage was
restricted to those practices in England that had already agreed to
participate in linkage at the time of the study. However, among
participating practices, all patients were included in the linkage.
Study population
The study population includes patients identified in the MINAP dataset,
aged ≥40, who were hospitalized for acute coronary syndrome (ACS)
from 2003 to 2009, with a discharge diagnosis of STEMI, NSTEMI, it
excludes ACS without troponin elevation (unstable angina). Patients
who were discharged alive from the hospital to home were followed
from the date of hospital discharge up to the patient’s death, transfer
out of the general practice, or the last GPRD data collection date avail-
able for this study.
The MINAP data were used to describe the in-hospital treatment
strategy and diagnosis (based on the discharge diagnosis, cardiac
biomarkers, and electrocardiograms). The GPRD data were used to
describe age at discharge, gender, alcohol use, history of diabetes
mellitus, smoking status, body mass index, socioeconomic deprivation
status by quintiles,11 history of angina, MI, and ACS (at least 1 month
prior to the discharge date), lipid levels, and blood pressure measure-
ments (in 6 months prior to the discharge date). Counts and percen-
tages and means and standard deviations were calculated as
appropriate. These descriptive analyses were presented separately
for those patients who did or did not receive a GP prescription for
clopidogrel within 3 months of hospital discharge.
Clopidogrel prescribing and discontinuation
Logistic regression was used to determine the characteristics associ-
ated with GP prescribing of clopidogrel within 3 months of hospital
discharge. Characteristics included the in-hospital presentation
(blood pressure and heart rate), treatment strategy (reperfusion strat-
egy and coronary intervention), and diagnosis recorded in MINAP,
demographics (age, gender, socioeconomic status, calendar year, and
geographical region), medical history (diabetes mellitus and angina/
MI), prior GP prescribing (clopidogrel, aspirin, and warfarin), and life-
style behaviours (alcohol consumption, smoking status, and body
mass index) recorded in GPRD, and prior hospitalizations (all cause
and cardiovascular related) recorded in HES. If there were no
records of body mass index, smoking status, or alcohol consumption,
indicators of missingness were used. Odds ratios and 95% confidence
intervals were calculated. As statins are routinely prescribed following
ACS, information on statin discontinuation was used to compare
clopidogrel discontinuation with another evidence-based treatment.
Discontinuation of clopidogrel or statin was defined as no prescrip-
tions for the medication within a period defined as the estimated dur-
ation of the prescription plus a grace period of 91 days. Cox regression
was used to assess the same set of characteristics for association with
clopidogrel discontinuation within the first year of discharge, with the
additional time-dependent characteristic of any bleeding within the
treatment period. Clopidogrel prescription on hospital discharge was
included only in the MINAP dataset after 2005, and had no duration
information associated with it, so this parameter was not analysed in
this study. Bleeding was defined as any bleeding event (major or
minor) in the patient’s GPRD or HES record. Hazard ratios (HRs)
and 95% confidence intervals were calculated.
Outcomes
Patients were followed for up to 1 year for incidences of subsequent
MI (as recorded in MINAP, GPRD, or HES) or death (as recorded in
the national death certificate data). Descriptive Cox regression was
used to identify the characteristics associated with these outcomes.
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Characteristics included discharge diagnosis, age, gender, socioeco-
nomic status, medical history, calendar year, region, and clopidogrel
treatment. Clopidogrel treatment following discharge was entered
into the model as a time-dependent covariate, with the following
categories: no treatment, 0 to ,3 months use, 3 to ,11 months
use, 11+ months use, and discontinued use. This allowed a patient
to move from one categorization of clopidogrel exposure to
another over time.
All data were analysed using Stata version 11.1 (Copyright 2009
StataCorp LP, College Station, TX, USA).
Results
Patients
The patient flow diagram (Figure 1) shows the number of patients
included in the study, with reasons for exclusion. A total of 23 740
patients in the linked MINAP–GPRD dataset included those with
non-ACS diagnoses and those outside the study period,
and those not meeting the inclusion criteria (Figure 1): 7543 met
inclusion criteria for this study. Specifically, these were patients
aged ≥40, discharged from hospital to home from 2003
onwards with a diagnosis of NSTEMI or STEMI. Patient character-
istics, stratified by discharge diagnosis and receipt of a primary care
prescription for clopidogrel within 3 months of discharge, are
shown in Tables 1 and 2. Only 68.6% of patients with NSTEMI,
and 62.8% of patients with STEMI, received a primary care clopido-
grel prescription in the first 3 months. Clopidogrel discontinuation,
after the first prescription, was substantially more frequent com-
pared with statins, both for NSTEMI and for STEMI (Figure 2).
Clopidogrel prescribing
Clopidogrel prescription within first 3 months: temporal
trends
The adjusted odds of receiving a primary care clopidogrel prescrip-
tion (Figure 3) in the first 3 months increased from 1.45 (95% CI,
1.11–1.89) in 2004 to 5.78 (95% CI, 4.20–7.96) in 2009. The
odds were higher in younger age groups, and decreased progress-
ively with advancing age: age 70–79 years, 0.64 (95% CI, 0.47–
0.85); 80+ years, 0.52 (95% CI, 0.39–0.71) compared with age
40–49 years. In patients managed with percutaneous intervention
during the hospital admission, the odds of receiving a clopidogrel
prescription were substantially higher, 6.19 (4.80–7.99), compared
with patients in whom no coronary intervention was performed.
Clopidogrel prescribing increased over time from 35% in 2003
to 79% in 2009.
Clopidogrel discontinuation during first year
In patients prescribed clopidogrel in the 3 months following
discharge (NSTEMI, 2820; STEMI, 1830), the odds of a patient
still being prescribed clopidogrel at 12 months were similar for
NSTEMI [53% (95% CI, 51–55)] and STEMI [54% (95% CI,
52–56)] patients. However, clopidogrel prescribing, in the same
patients, declined more rapidly than that for statins: statin prescrib-
ing in NSTEMI was 84% (95% CI, 82–85) and in STEMI was 89%
(95% CI, 87–90).
Figure 1 Study population disposition.
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Table 1 Demographics and medical history of patients by discharge diagnosis and primary care clopidogrel
prescription within 3 months
NSTEMI STEMI
No clopidogrela
(n5 1288)
Clopidogrela
(n 5 2820)
No clopidogrela
(n 5 1085)
Clopidogrela
(n5 1830)
Age (years), n (%)
40–49 42 (3.3) 158 (5.6) 91 (8.4) 209 (11.4)
50–59 98 (7.6) 401 (14.2) 216 (19.9) 403 (22.0)
60–69 198 (15.4) 576 (20.4) 249 (22.9) 521 (28.5)
70–79 417 (32.4) 794 (28.2) 298 (27.5) 416 (22.7)
80+ 533 (41.4) 891 (31.6) 231 (21.3) 281 (15.4)
Gender, n (%)
Male 738 (57.3) 1777 (63.0) 765 (70.5) 1309 (71.5)
Female 550 (42.7) 1043 (37.0) 320 (29.5) 521 (28.5)
Smoking status, n (%)
Non-smoker 450 (34.9) 907 (32.2) 333 (30.7) 489 (26.7)
Ex smoker 539 (41.8) 1220 (43.3) 329 (30.3) 659 (36.0)
Smoker 254 (19.7) 634 (22.5) 363 (33.5) 626 (34.2)
Unknown smoking status 45 (3.5) 59 (2.1) 60 (5.5) 56 (3.1)
Obesity, n (%)
Underweight (BMI ,20) 63 (4.9) 130 (4.6) 52 (4.8) 53 (2.9)
Normal (BMI 20 to ,25) 360 (28.0) 707 (25.1) 319 (29.4) 474 (25.9)
Overweight (BMI 25 to ,30) 462 (35.9) 1125 (39.9) 428 (39.4) 763 (41.7)
Obese (BMI .30) 297 (23.1) 717 (25.4) 225 (20.7) 446 (24.4)
Unknown BMI 106 (8.2) 141 (5.0) 61 (5.6) 94 (5.1)
Socioeconomic deprivation, n (%)
0 (least deprived quintile) 169 (13.1) 419 (14.9) 160 (14.7) 292 (16.0)
1 285 (22.1) 583 (20.7) 241 (22.2) 386 (21.1)
2 293 (22.7) 589 (20.9) 248 (22.9) 367 (20.1)
3 274 (21.3) 606 (21.5) 215 (19.8) 375 (20.5)
4 (most deprived quintile) 267 (20.7) 623 (22.1) 221 (20.4) 410 (22.4)
History of diabetes 320 (24.8) 624 (22.1) 134 (12.4) 212 (11.6)
Prior medical history, n (%)
No history of angina or MI 724 (56.2) 1672 (59.3) 876 (80.7) 1526 (83.4)
History of stable angina only 417 (32.4) 836 (29.6) 129 (11.9) 180 (9.8)
History of unstable angina only 22 (1.7) 48 (1.7) 5 (0.5) 12 (0.7)
History of MI 125 (9.7) 264 (9.4) 75 (6.9) 112 (6.1)
Prior medication in primary care, n (%)
Clopidogrel 94 (7.3) 339 (12.0) 20 (1.8) 84 (4.6)
Aspirin 624 (48.4) 1339 (47.5) 270 (24.9) 442 (24.2)
Antiplatelet 667 (51.8) 1477 (52.4) 283 (26.1) 475 (26.0)
Warfarin 190 (14.8) 113 (4.0) 47 (4.3) 41 (2.2)
Test results in 6 months prior to event
Total cholesterol measured
n (%) 495 (38.4) 1206 (42.8) 356 (32.8) 634 (34.6)
Mean (SD) 4.7 (1.3) 4.9 (1.3) 5.2 (1.3) 5.2 (1.7)
HDL cholesterol measured
n (%) 321 (24.9) 813 (28.8) 206 (19.0) 408 (22.3)
Mean (SD) 1.4 (0.4) 1.3 (0.4) 1.3 (0.4) 1.3 (0.4)
Continued
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The adjusted HRs for clopidogrel discontinuation showed no
significant change during the study period (Figure 4). The hazard
for discontinuation was higher in patients aged .80 [HR 1.50
(95% CI, 1.16–1.94)], and those who had a bleeding event after
leaving hospital [HR 1.34 (95% CI, 1.03–1.73)]. The adjusted
hazard for clopidogrel discontinuation differed in those following
in-hospital percutaneous coronary intervention (PCI) [HR 0.72
(95% CI, 0.63–0.83)] and no in-hospital PCI (Figure 4) but discon-
tinuation tended to be more frequent following coronary artery
bypass graft (CABG) [HR 1.82 (95% CI, 0.99–3.35)].
Bleeding events
In patients prescribed clopidogrel in primary care within 3 months
of discharge, the rates of bleeding per 100 patient-years were
similar following NSTEMI 12.03 (95% CI, 10.62–13.64) and
STEMI 10.55 (95% CI, 8.96–12.42); overall 11.44 (95% CI,
10.36–12.63).
Death and non-fatal myocardial infarction
In patients prescribed clopidogrel in primary care, the rate of death
and non-fatal MI in the first year post discharge (per 100 person-
years) was 18.15 (95% CI, 16.83–19.58) overall; 22.42 (95% CI,
20.54–24.48) following NSTEMI, 11.69 (95% CI, 10.07–13.57)
following STEMI. In those who did not receive a prescription
within 3 months, the rate was 36.69 (95% CI, 34.14–39.41)
overall; 48.42 (95% CI, 44.43–52.76) following NSTEMI, and
23.55 (95% CI, 20.67–26.83) following STEMI.
Adjusted HRs for death or non-fatal MI in the first year following
discharge are shown in Figure 5. Hazard was higher for NSTEMI
compared with STEMI and increased progressively with age and depri-
vation status. Clopidogrel prescribing was associated with a lower
hazard of death or non-fatal MI compared with patients who received
no prescriptions [months 0 to ,3, HR 0.61 (95% CI, 052–0.72);
months 3–11, HR 0.53 (95% CI, 0.44–0.65); 11+ months, HR 0.68
(95% CI, 0.50–0.92)]. This descriptive analysis found that clopidogrel
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Table 2 Interventions performed during admission for index myocardial infarction: non-ST-elevation myocardial
infarction or ST-elevation myocardial infarction discharge diagnosis and primary care clopidogrel prescription within 3
months
Characteristics NSTEMI, n (%) STEMI, n (%)
No clopidogrel
(n 5 1288)
Clopidogrel
(n5 2820)
No clopidogrel
(n 5 1085)
Clopidogrel
(n5 1830)
No reperfusion treatment 1234 (95.8) 2699 (95.7) 172 (15.9) 374 (20.4)
In-hospital thrombolytic treatment 27 (2.1) 44 (1.6) 779 (71.8) 865 (47.3)
Primary PCI 0 (0.0) 9 (0.3) 30 (2.8) 352 (19.2)
Other, blank, or unknown 27 (2.1) 68 (2.4) 106 (9.6) 239 (13.1)
No coronary intervention performed 1119 (86.9) 1966 (69.7) 949 (87.5) 855 (46.7)
PCI 53 (4.1%) 574 (20.4%) 63 (5.8%) 740 (40.4%)
CABG 31 (2.4%) 10 (0.4%) 7 (0.6%) 9 (0.5%)
Other, blank, or unknown 85 (6.6%) 270 (9.6%) 66 (6.1%) 226 (12.3%)
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Table 1 Continued
NSTEMI STEMI
No clopidogrela
(n 5 1288)
Clopidogrela
(n 5 2820)
No clopidogrela
(n 5 1085)
Clopidogrela
(n5 1830)
LDL cholesterol measured
n (%) 231 (17.9) 620 (22.0) 155 (14.3) 312 (17.0)
Mean (SD) 2.7 (1.0) 2.8 (1.1) 3.1 (1.1) 3.0 (1.1)
Triglycerides measured
n (%) 319 (24.8) 797 (28.3) 206 (19.0) 416 (22.7)
Mean (SD) 1.7 (1.2) 1.7 (1.1) 1.8 (1.0) 1.8 (1.2)
Systolic BP measured
n (%) 962 (74.7) 2008 (71.2) 598 (55.1) 1014 (55.4)
Mean (SD) 138.9 (21.8) 139.5 (21.7) 141.0 (21.0) 139.3 (20.3)
Diastolic BP measured
n (%) 962 (74.7) 2008 (71.2) 598 (55.1) 1014 (55.4)
Mean (SD) 76.0 (12.3) 77.2 (12.5) 79.6 (11.2) 79.7 (12.2)
aWhether or not a patient was prescribed clopidogrel in primary care within 3 months of ACS event.
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discontinuation within 12 months was independently associated with
an increased risk of death or MI both compared with untreated
patients [HR 1.45 (1.22–1.73)] and with those patients persisting
with clopidogrel treatment [HR 2.62 (2.17–3.17)].
Discussion
This study provides the first analysis using linked national registries
to define persistence with clopidogrel therapy among patients
discharged from hospital after acute MI. The observations were
compared with statin prescribing in the same population. The
data show that clopidogrel persistence, as reflected by prescription
rates, declines steeply in the first 12 months, particularly in older
patients and those who have a bleeding event. An even steeper
decline is observed after 12 months (Figure 2), consistent with
many guideline recommendations.1– 4
The findings contrast with the more gradual decline in statin
prescribing in these patients. In this observational analysis, discon-
tinuation of clopidogrel prescription after acute MI is associated
with a significant increase in the risk of death or recurrent infarc-
tion during the first 12 months, even after adjustment for baseline
variables. Nevertheless, the possibility exists that unmeasured
variables may have influenced this association and the observation
does not establish causality.
Guideline recommendations are for clopidogrel to continue for
12 months in patients with NSTEMI and in those patients with
STEMI who receive drug-eluting stents.1 –4 Yet, we found that in
around half of all patients with NSTEMI, prescription of clopidogrel
was discontinued within the first 12 months after discharge from
hospital. However, discontinuation was less frequent in NSTEMI
patients who underwent PCI intervention [HR 0.72 (95% CI,
0.63–0.83)]. The pattern was similar for STEMI and, regardless
of the type of infarction, showed little year-on-year change
during the course of the study. The trajectory of decline for clopi-
dogrel prescription in the first 12 months was steeper than that for
statins, suggesting that it was driven by factors additional to the
patient-related influences associated with under-treatment (for
example, general patient compliance issues). Thus, the relation
between advanced age and the under-use of evidence-based
treatment has widely been reported and was demonstrated for
clopidogrel in the present study.12 However, side-effects and com-
plications of treatment also influence prescribing, and our finding
that bleeding events were associated with discontinuation of clopi-
dogrel was not unexpected. Rates of major and non-major bleed-
ing (NSTEMI 12 per 100 patient-years) were higher than observed
in the original randomized trial (8.5% rate of all bleeds, for a
median duration of 9 months), but this observational study reflects
the spectrum of patients in clinical practice, rather than the trial
population.13
The main finding in the present study was the association
between clopidogrel discontinuation in the first 12 months and
the outcome following either NSTEMI or STEMI. Clopidogrel pre-
scription during this period was associated with a reduction in the
hazard of death or non-fatal MI compared with patients who
received no prescription, consistent with trial evidence of clopido-
grel’s prognostic benefit in patients with acute coronary
syndromes.13 Importantly, among those patients prescribed
clopidogrel who then had it discontinued, the hazard of death or
non-fatal MI was significantly greater compared with patients who
continued to receive a clopidogrel prescription. The hazards of
death and MI (including the impact of withdrawal of anti-thrombotic
therapy) associated with bleeding have been recognized in trial
data14 and in the European Guidelines.4 For statin treatment,
there is corresponding evidence indicating that the benefits of
treatment may only be sustained through continued use of these
drugs.8
Figure 2 Discontinuation of clopidogrel and statin prescribing in primary care following non-ST-elevation myocardial infarction or
ST-elevation myocardial infarction.
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Our findings of an increased hazard of death and non-fatal MI
associated with discontinuation of clopidogrel are consistent with
those of Ho et al.7 who reported that any delay in filling clopidogrel
prescriptions after hospital discharge in patients treated with
drug-eluting stents was associated with nearly twice the rate of cor-
onary events during follow-up for 22 months. Again it was older
Figure 3 Characteristics associated with primary care clopidogrel prescribing within 3 months of hospital discharge.
R. Boggon et al.2382
patients who were more likely, than younger patients, to delay filling
their prescriptions. Our findings are also consistent with other
observational studies in US and Australian populations where
discontinuation of clopidogrel therapy within a year of stent was
associated with worse outcomes.15– 17 Clopidogrel discontinuation
was associated with bleeding. In all these situations, the adverse
Figure 4 Characteristics associated with discontinuation of primary care clopidogrel prescribing within 1 year of hospital discharge.
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consequences of clopidogrel withdrawal are presumed mediated by
changes in platelet activation triggering thrombotic events. It is plaus-
ible that similar mechanisms drove the association between
clopidogrel discontinuation and adverse outcomes in the present
study although in the absence of platelet function data and cause-
specific mortality data the interpretations must be cautious.
Figure 5 Characteristics associated with death or myocardial infarction in the first year post hospital discharge.
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A major strength of our study was the use of MINAP, the
national registry of acute coronary syndromes, which we linked
with GPRD to obtain longitudinal primary healthcare data with
which to document outpatient prescription of clopidogrel and its
relation to death and non-fatal infarction. An additional strength
was the reference to statin prescribing in the same patients
(Figure 2). These findings suggest that characteristics of the
treatments, rather than the patients, were responsible for the
differences observed.
Our study has important limitations which are inherent in any
large registry analysis. Data on hospital clopidogrel prescribing,
both during the admission and on discharge, were not comprehen-
sively recorded and was not included in the study. Although GP pre-
scription information was robust, we do not know whether
clopidogrel was collected or taken by individual patients, or was pre-
scribed by a third party. This limited the focus of the study to clopi-
dogrel prescriptions within primary care. Also, we cannot determine
whether the association between clopidogrel discontinuation and
adverse events was causal or was confounded by the influence of
unrecorded co-morbidities or bleeding events.13,16– 18 The analysis
undertaken was descriptive, rather than hypothesis testing, and
further research, incorporating more complex statistical method-
ologies, is required to fully investigate the association found. Rates
of intervention were lower in this study than contemporary
studies outside the UK, and lower than the current rates in the
UK.19,20 Primary PCI is now the dominant treatment for STEMI.19
At the time of this study, .80% of patients with STEMI received
reperfusion treatment, but this was mainly with thrombolysis
(Table 2). MINAP was designed to capture all patients with STEMI
and NSTEMI, but it did not capture all patients with unstable
angina, and such patients were excluded from this analysis.
Healthy user bias is difficult to avoid in studies of this type;
however, similar healthy user bias will apply to prescribing of
statins which showed a slower decline in prescribing than clopido-
grel.18 Although our outcome analysis was adjusted for baseline
factors that included prior coronary events and hospitalizations
(all cause and cardiovascular), we do not know whether the
patients who discontinued clopidogrel were predisposed to
adverse outcomes through other mechanisms.
In conclusion, this study has demonstrated the feasibility of
linking a nationwide in-hospital registry programme (MINAP)
with general practitioner and outcome survival data. This is the
first study to use linked registries to determine the prognostic
associations of clopidogrel discontinuation in patients discharged
from hospital after NSTEMI and STEMI. Our data show that
discontinuation of clopidogrel during the first 12 months is
common, particularly in older patients, and associated with an
increased risk of death or recurrent MI. This study does not estab-
lish that the association between discontinuation and death or MI is
causal. Nonetheless, discontinued prescribing of clopidogrel ahead
of guideline recommendations must be treated with caution, and
strategies to promote the appropriate use of secondary prevention
treatment in this high-risk group of patients are required.
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